Zobrazeno 1 - 10
of 195
pro vyhledávání: '"Akihide, Matsumura"'
Autor:
Akihiro Tamiya, Yasuhiro Koh, Shun‐ichi Isa, Akihito Kubo, Masahiko Ando, Hideo Saka, Naoki Yoshimoto, Sadanori Takeo, Hirofumi Adachi, Tsutomu Tagawa, Osamu Kawashima, Motohiro Yamashita, Kazuhiko Kataoka, Mitsuhiro Takenoyama, Yukiyasu Takeuchi, Katsuya Watanabe, Akihide Matsumura, Tomoya Kawaguchi
Publikováno v:
Cancer Medicine, Vol 9, Iss 7, Pp 2343-2351 (2020)
Abstract Background To report the follow up data and clinical outcomes of the JME study (UMIN 000008177), a prospective, multicenter, molecular epidemiology examination of 876 surgically resected non‐small‐cell lung cancer (NSCLC) cases, and the
Externí odkaz:
https://doaj.org/article/5683b6fa5c354da5939ae03f12b109d8
Autor:
Kensuke Kojima, Hyungeun Yoon, Tetsuki Sakamoto, Tomoki Utsumi, Teiko Sakurai, Naoko Takeuchi, Maiko Takeda, Takahiko Kasai, Shinji Atagi, Akihide Matsumura
Publikováno v:
Surgical Case Reports, Vol 5, Iss 1, Pp 1-6 (2019)
Abstract Background Fetal adenocarcinoma of the lung is a rare lung neoplasm that accounts for only 0.5% of all primary lung cancers. Because of its rarity, effective treatments for the management of the tumor are poorly understood. We herein report
Externí odkaz:
https://doaj.org/article/fc27664cd8b9484eb44286688f120b52
Autor:
Keiju Aokage, Kenji Suzuki, Hisashi Saji, Masashi Wakabayashi, Tomoko Kataoka, Yuta Sekino, Haruhiko Fukuda, Makoto Endo, Aritoshi Hattori, Takahiro Mimae, Tomohiro Miyoshi, Mitsuhiro Isaka, Hiroshige Yoshioka, Ryu Nakajima, Kazuo Nakagawa, Jiro Okami, Hiroyuki Ito, Hiroaki Kuroda, Masahiro Tsuboi, Norihito Okumura, Makoto Takahama, Yasuhisa Ohde, Tadashi Aoki, Yasuhiro Tsutani, Morihito Okada, Shun-ichi Watanabe, Yukinori Sakao, Sakae Okumura, Toshihiko Iizasa, Ichiro Yoshino, Atsushi Fujita, Masahiro Yoshimura, Yuji Asato, Haruhiko Nakayama, Isao Matsumoto, Tetsuya Mitsudomi, Takashi Marutsuka, Makoto Suzuki, Haruhiko Kondo, Hiroshi Date, Takeshi Nagayasu, Kohei Yokoi, Shunichi Watanabe, Akihide Matsumura, Yoshinori Yamashita, Kiyoshi Ishikawa, Motohiro Yamashita, Yasuki Saito, Mitsuhiro Takenoyama, Katsuo Yoshiya, Kenji Sugio, Shinichiro Miyoshi, Yoshihisa Kadota, Masahiko Higashiyama, Meinoshin Okumura, Hirohiko Akiyama, Akinori Iwasaki, Haruhiko Nakamura, Haruhisa Matsuguma, Takashi Kondo, Norihiko Ikeda, Hirotoshi Horio, Toru Sato, Takuya Nagashima, Akira Yoshizu, Hiromi Katsuki, Mingyon Mun, Kouhei Tajima, Wataru Nishio, Moriyuki Kiyoshima, Masashi Kobayashi, Masaki Anraku, Toyofumi Yoshikawa, Hyung-eun Yoon, Takeshi Mimura, Tsutomu Kawabata, Tohru Hasumi, Tatsuro Okamoto, Shinichi Toyooka, Yasushi Shintani, Tomomi Hirata, Yoshinori Okada, Tetsukan Woo, Mai Daido
Publikováno v:
The Lancet Respiratory Medicine. 11:540-549
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a4e7c80bdf03639d3658351f850c2ea
https://doi.org/10.1016/s2213-2600(23)00041-3
https://doi.org/10.1016/s2213-2600(23)00041-3
Autor:
Masahiko Ando, Yoshihiko Taniguchi, Akihiro Tamiya, Akihide Matsumura, Koichi Ogawa, Yasuhiro Koh, Hiroyasu Kaneda, Motohiro Izumi, Yoshiya Matsumoto, Kenji Sawa, Mitsuru Fukui, Naoki Yoshimoto, Akihito Kubo, Shun-ichi Isa, Hideo Saka, Tomoya Kawaguchi
Publikováno v:
BMJ Open, Vol 10, Iss 9 (2020)
Externí odkaz:
https://doaj.org/article/21d6aa93cb0a46079c661df2bf121902
Autor:
Masaru Watanabe, Tomoya Kawaguchi, Shun-ichi Isa, Masahiko Ando, Akihiro Tamiya, Akihito Kubo, Hideo Saka, Sadanori Takeo, Hirofumi Adachi, Tsutomu Tagawa, Osamu Kawashima, Motohiro Yamashita, Kazuhiko Kataoka, Yukito Ichinose, Yukiyasu Takeuchi, Katsuya Watanabe, Akihide Matsumura, Yasuhiro Koh
Publikováno v:
EBioMedicine, Vol 21, Iss C, Pp 86-93 (2017)
Epidermal growth factor receptor (EGFR) mutations have been used as the strongest predictor of effectiveness of treatment with EGFR tyrosine kinase inhibitors (TKIs). Three most common EGFR mutations (L858R, exon 19 deletion, and T790M) are known to
Externí odkaz:
https://doaj.org/article/38c362f4c73e4f60970434713501eaf5
Autor:
Yasuhiro Koh, Akihide Matsumura, Kazuhiro Sakamoto, Yukiyasu Takeuchi, Yukito Ichinose, Kazuhiko Kataoka, Motohiro Yamashita, Seiichi Kakegawa, Tsutomu Tagawa, Hirofumi Adachi, Sadanori Takeo, Hideo Saka, Akihito Kubo, Akihiro Tamiya, Masahiko Ando, Shun-ichi Isa, Tomoya Kawaguchi, Masaru Watanabe
Purpose: The resistance to the EGFR tyrosine kinase inhibitors (TKI) is a major concern in non–small cell lung cancer (NSCLC) treatment. T790M mutation in EGFR accounts for nearly 50% of the acquired resistance to EGFR-TKIs. Earlier studies suggest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b3ad8790d0f4439ce3f54024f02594
https://doi.org/10.1158/1078-0432.c.6523212.v1
https://doi.org/10.1158/1078-0432.c.6523212.v1
Autor:
Yasuhiro Koh, Akihide Matsumura, Kazuhiro Sakamoto, Yukiyasu Takeuchi, Yukito Ichinose, Kazuhiko Kataoka, Motohiro Yamashita, Seiichi Kakegawa, Tsutomu Tagawa, Hirofumi Adachi, Sadanori Takeo, Hideo Saka, Akihito Kubo, Akihiro Tamiya, Masahiko Ando, Shun-ichi Isa, Tomoya Kawaguchi, Masaru Watanabe
Supplementary Figures S1-8. Figure S1: Flowchart for mutation call. Figure S2: Quantification of performance of ddPCR analysis for EGFR T790M mutation. Figure S3: Analytical sensitivity of 0.001% for the ddPCR assay. Figure S4: Determination of false
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4242036600537831c53f664f345297d5
https://doi.org/10.1158/1078-0432.22456137.v1
https://doi.org/10.1158/1078-0432.22456137.v1
Autor:
Yasuhiro Koh, Akihide Matsumura, Kazuhiro Sakamoto, Yukiyasu Takeuchi, Yukito Ichinose, Kazuhiko Kataoka, Motohiro Yamashita, Seiichi Kakegawa, Tsutomu Tagawa, Hirofumi Adachi, Sadanori Takeo, Hideo Saka, Akihito Kubo, Akihiro Tamiya, Masahiko Ando, Shun-ichi Isa, Tomoya Kawaguchi, Masaru Watanabe
Supplementary Materials and Methods, Reference and Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cca6562ace6fa0272ed1b5b35964ddd
https://doi.org/10.1158/1078-0432.22456140.v1
https://doi.org/10.1158/1078-0432.22456140.v1
Autor:
Yasuhiro Koh, Akihide Matsumura, Kazuhiro Sakamoto, Yukiyasu Takeuchi, Yukito Ichinose, Kazuhiko Kataoka, Motohiro Yamashita, Seiichi Kakegawa, Tsutomu Tagawa, Hirofumi Adachi, Sadanori Takeo, Hideo Saka, Akihito Kubo, Akihiro Tamiya, Masahiko Ando, Shun-ichi Isa, Tomoya Kawaguchi, Masaru Watanabe
Supplementary Tables S1-5. Table S1: Primers and probes used for droplet digital PCR (ddPCR). Table S2: Determination of the limit of blank (LOB) from wild-type control DNA, normal human genomic DNA, and EGFR wild-type A549 genomic DNA. Table S3: Det
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::520406ecc177aca83747293358d78716
https://doi.org/10.1158/1078-0432.22456134.v1
https://doi.org/10.1158/1078-0432.22456134.v1
Autor:
Maiko Takeda, Takahiko Kasai, Maiko Naito, Akihiro Tamiya, Yoshihiko Taniguchi, Nobuhiko Saijo, Yoko Naoki, Kyoichi Okishio, Shigeki Shimizu, Kensuke Kojima, Akihiro Nagoya, Tetsuki Sakamoto, Tomoki Utsumi, Hyung-Eun Yoon, Akihide Matsumura, Shinji Atagi
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 13 (2019)
Background: In recent years, the anti-programmed cell death 1 (PD-1) drug pembrolizumab (Keytruda) was approved for treatment of unresectable advanced non-small cell lung cancer (NSCLC) as first- or second-line therapy depending on the clone 22C3-pro
Externí odkaz:
https://doaj.org/article/ace52606b2ff4f32aa3d94e58e47b748